Benchmark Capital Move
Benchmark upgraded Integer Holding (NYSE: ITGR) to Buy from Hold on Thursday and assigned a price target of $95. The firm said its valuation implies roughly 1.7 times estimated 2026 revenues, a multiple driven in part by what Benchmark described as a positive rebound in the company’s quarterly financial performance in the fourth quarter of 2025.
Quarterly results in focus
Integer reported fourth-quarter 2025 revenue of $472.1 million, a 5% increase year-over-year, topping Benchmark’s internal estimate of $460 million. Adjusted earnings came in at $1.76 per share, versus $1.43 a year earlier, and beat Benchmark’s forecast of $1.66.
The company’s Cardio & Vascular business recorded 11.3% year-over-year sales growth for the quarter. That segment’s performance included 4.4% organic growth, which the company attributed to recent acquisitions - Precision Coating and VSI Parylene - alongside demand for Neurovascular devices.
Guidance and capital allocation
Management reiterated its 2026 financial guidance and narrowed the guidance range toward the midpoint. During the quarter Integer completed $50 million of share repurchases, acquiring roughly 700,000 shares, and announced an additional $50 million accelerated share repurchase program.
Valuation and third-party analysis
Data from InvestingPro indicated shares are trading at a price-to-earnings ratio of 29.92 and a market capitalization of $2.91 billion. The platform’s Fair Value output places Integer among names it considers among the most undervalued, suggesting potential upside from current market levels. InvestingPro also noted availability of a comprehensive Pro Research Report on Integer as part of its broader report library.
Additional earnings details and market reaction
In related reporting of its fourth-quarter 2025 results, Integer posted EPS of $1.76, exceeding a Wall Street consensus figure of $1.70. Revenue for the period was reported at $472 million versus an anticipated $462.72 million. Despite the stronger-than-expected performance and the company’s capital return activity, the reporting noted an absence of merger announcements. It was also recorded that no analyst upgrades or downgrades were reported following the earnings release.
What this means
The combination of revenue and adjusted EPS beats, segment-level growth concentrated in Cardio & Vascular, a narrowed 2026 guidance range, and active share repurchase programs framed Benchmark’s decision to move the rating to Buy and set the $95 target. InvestingPro valuation metrics are being highlighted alongside those operational results as data points investors may weigh.